{"allTrials": {"@totalCount": "11", "@xmlns": "http://www.67bricks.com/isrctn", "fullTrial": [{"trial": {"@lastUpdated": "2008-11-13T00:00:00.000Z", "@version": "24", "isrctn": {"@dateAssigned": "2008-09-12T00:00:00.000Z", "#text": "27670575"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Controlling Tungiasis in an Impoverished Community", "scientificTitle": "Controlling tungiasis in an impoverished community: an intervention study", "acronym": "CTIC", "studyHypothesis": "The implementation of various control measures will result in a drop of prevalence and intensity of infestation of tungiasis.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Proportion of individuals infested with Tunga penetrans (Prevalence of tungiasis), measured 10 times during the 12 months study period in equal intervals. Reduction of prevalence was measured through comparison with the baseline level.", "secondaryOutcome": "Number of embedded sand fleas per infested individual, measured 10 times during the 12 months study period in equal intervals. This intensity of infestation was measured in terms of categories and total number, both compared to baseline levels.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethical Review Board of the Federal University of Cear\u00e1. Date of approval: 25/10/2002 (ref: 195/02)"}, "externalRefs": {"doi": "10.1186/ISRCTN27670575", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "195/02"}, "trialDesign": {"studyDesign": "Non-randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Non randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2002-11-14T00:00:00.000Z", "overallEndDate": "2003-11-20T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Brazil", "Germany"]}, "trialCentres": {"trialCentre": {"@id": "20fdb791-4000-4f60-82c8-64fcf908a7d2", "name": "Institute for Microbiology and Hygiene", "address": null, "city": "Berlin", "state": null, "country": "Germany", "zip": "12203"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Inhabitants of all age groups, both males and females, were eligible for the study, provided they had spent at least four days per week in the village during the last three months\n2. Informed written consent obtained from study participant and carers", "ageRange": "Other", "gender": "Both", "targetEnrolment": "831", "totalFinalEnrolment": null, "totalTarget": "831", "exclusion": "1. Absence from the study area for more than 4 days per week\n2. Unwillingness to participate", "patientInfoSheet": null, "recruitmentStart": "2002-11-14T00:00:00.000Z", "recruitmentEnd": "2003-11-20T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Tungiasis (Tunga penetrans [sand flea] infestation)", "diseaseClass1": "Infections and Infestations", "diseaseClass2": "Other infestations"}}, "interventions": {"intervention": {"description": "One village served as the intervention village and the other served as the control village.  \n\nTarget number of recruitment: 597 individuals in the intervention village and 234 individuals in the control village (total 831). The actual number of people living in the villages was 630 for the intervention village and 281 for the control village. \n\nIntervention village: From November 2002 through January 2003, from all infested individuals, embedded sand fleas were extracted every two to three weeks by experienced health care professionals under sterile conditions. The remaining sore was treated with an antibiotic ointment. During the same period all cats and dogs were treated with trichlorphone 97% in oily solution (Neguvon\u00ae, Bayer do Brasil, Brazil) or neck collars impregnated with propoxur and flumethrin (Kiltix\u00ae, Bayer Bayer do Brasil, Brazil). In February 2003, deltamethrin was used for focal premise treatment. Focal spraying was performed by trained personnel of the Health Secretariat of Cascavel Municipality. The insecticide was sprayed on the ground next to the houses targeting areas in which off-host development of T. penetrans was suspected to occur, such as preferred whereabouts of dogs and cats, and shady places under trees, or inside houses in the case of a sandy floor. Focal premise treatment using insecticides was repeated twice during a period of six weeks.\n \nNo intervention took place in the control village.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18941513 Results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "a5c8d32e-5a54-4d80-8996-8b550f84356a", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2008-11-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/18941513"}, "description": "Results", "productionNotes": null}}, "parties": {"funderId": "Funder17980-0", "contactId": "Contact55963_17980", "sponsorId": "Sponsor54527"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55963_17980", "title": "Prof", "forename": "Hermann", "surname": "Feldmeier", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Institute for Microbiology and Hygiene\nCharite - University Medicine Berlin \nCampus Benjamin Franklin\nHindenburgdamm 27", "city": "Berlin", "country": "Germany", "zip": "12203", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor54527", "organisation": "Mandacaru Foundation (Brazil)", "website": "http://www.mandacaru-foundation.org", "sponsorType": "Charity", "contactDetails": {"address": "Rua Jos\u00e9 Vilar de Andrade 257", "city": "Fortaleza", "country": "Brazil", "zip": "CE 60833-830", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.487456.c", "rorId": "https://ror.org/05h876969"}, "funder": {"@id": "Funder17980-0", "name": "Mandacaru Foundation (Brazil)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-11-13T00:00:00.000Z", "@version": "24", "isrctn": {"@dateAssigned": "2008-08-21T00:00:00.000Z", "#text": "01779485"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Epidemiology and treatment of soil-transmitted helminthiasis, with particular consideration to strongyloidiasis, in Yunnan province, China", "scientificTitle": null, "acronym": null, "studyHypothesis": "1. Single-dose albendazole and single-dose tribendimidine (both drugs will be administered orally at 200 mg for children aged 5-14 years, and 400 mg for individuals aged >=15 years) are safe and efficacious against soil-transmitted helminth infections (Ascaris lumbricoides, hookworm and Trichuris trichuria) \n2. Single-dose tribendimidine has an effect on Strongyloides stercoralis and Taenia spp", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Reduction of infection prevalence of intestinal helminths, assessed by examination of stool samples 2-4 weeks after drug administration \n2. Frequency and severity of adverse events were recorded within 24 hours after drug administration", "secondaryOutcome": "Kato-Katz-derived egg count reduction of common soil-transmitted helminths, assessed 2-4 weeks after drug administration.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics Committee of the University and the State of Basel (Ethikkommission beider Basel) (EKBB) Date of approval: 12/06/2007 (ref: 149/07)"}, "externalRefs": {"doi": "10.1186/ISRCTN01779485", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Open-label, randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2007-05-01T00:00:00.000Z", "overallEndDate": "2007-07-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["China", "Switzerland"]}, "trialCentres": {"trialCentre": {"@id": "7f7bedf1-c901-4119-b00a-8254c5bb28c1", "name": "Department of Public Health and Epidemiology", "address": null, "city": "Basel", "state": null, "country": "Switzerland", "zip": "4002"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Both males and females, age >=5 years\n2. Submission of >=1 stool sample for the baseline parasitological survey\n3. For females, not pregnant, as verbally assessed by medical personnel on the day of treatment\n4. Absence of major systemic illnesses, as assessed by medical personnel on the day of treatment\n5. Written informed consent by the head of the household on behalf of the whole family", "ageRange": "Other", "gender": "Both", "targetEnrolment": "300", "totalFinalEnrolment": null, "totalTarget": "Approximately 300", "exclusion": "1. Presence of any abnormal medical condition, as judged by the medical personnel\n2. No stool sample submitted for baseline parasitological survey\n3. Enrolled in any other clinical investigation during the study\n4. For females: pregnancy", "patientInfoSheet": null, "recruitmentStart": "2007-05-01T00:00:00.000Z", "recruitmentEnd": "2007-07-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Helminth infections", "diseaseClass1": "Infections and Infestations", "diseaseClass2": null}}, "interventions": {"intervention": {"description": "The participants who were diagnosed with helminthiases at the baseline parasitological survey were randomly allocated to the following arms: \n\nArm 1: Single-dose albendazole (oral), 200 mg for children aged 5-14 years, and 400 mg for individuals aged >=15 years\nArm 2: Single-dose tribendimidine (oral), 200 mg for children aged 5-14 years, and 400 mg for individuals aged >=15 years", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Albendazole, tribendimidine"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18923706 Results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "2b7c36bc-0a3b-4bdd-a276-efec05b6bf87", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2008-08-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/18923706"}, "description": "Results", "productionNotes": null}}, "parties": {"funderId": ["Funder18062-0", "Funder18062-1", "Funder18062-2", "Funder18062-3", "Funder18062-4", "Funder18062-5", "Funder18062-6"], "contactId": "Contact56049_18062", "sponsorId": "Sponsor54615"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56049_18062", "title": "Dr", "forename": "Juerg", "surname": "Utzinger", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Department of Public Health and Epidemiology\nSwiss Tropical Institute\nSocinstrasse 57\nPO Box", "city": "Basel", "country": "Switzerland", "zip": "4002", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+41 61 284 8129"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "juerg.utzinger@unibas.ch"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor54615", "organisation": "Swiss National Science Foundation (SNSF) (Switzerland)", "website": "http://www.snf.ch", "sponsorType": "Government", "contactDetails": {"address": "Wildhainweg 3\nPO Box 8232", "city": "Bern", "country": "Switzerland", "zip": "3001", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+41 31 308 22 22"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "info@snf.ch"}}, "privacy": "Public", "gridId": "grid.425888.b", "rorId": "https://ror.org/00yjd3n13"}, "funder": [{"@id": "Funder18062-0", "name": "Main funder:", "fundRef": null}, {"@id": "Funder18062-1", "name": "Commission for Research Partnership with Developing Countries (KFPE) through the Swiss Agency for Development and Cooperation (SDC) (Switzerland)", "fundRef": null}, {"@id": "Funder18062-2", "name": "Other funders:", "fundRef": null}, {"@id": "Funder18062-3", "name": "Voluntary Academic Society (Freiwillige Akademische Gesellschaft) (Switzerland)", "fundRef": null}, {"@id": "Funder18062-4", "name": "Janggen-P\u00f6hn Foundation (Janggen-P\u00f6hn-Stiftung) (Switzerland)", "fundRef": null}, {"@id": "Funder18062-5", "name": "Chinese Ministry of Science and Technology, through their support to the Key Laboratory of Parasite and Vector Biology of the Chinese Ministry of Health (China) (grant ref: 2005DKA21104)", "fundRef": null}, {"@id": "Funder18062-6", "name": "Swiss National Science Foundation (Switzerland) (project numbers PPOOB-102883 and PPOOB-119129)", "fundRef": "http://dx.doi.org/10.13039/501100001711"}]}, {"trial": {"@lastUpdated": "2008-11-13T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2007-06-27T00:00:00.000Z", "#text": "90535566"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Effect of breakfast cereals compared with corn flakes on blood glucose, gastric emptying and satiety in healthy subjects", "scientificTitle": "Effect of beta-glucan breakfast cereals compared with corn flakes on post-prandial blood glucose, gastric emptying and satiety in healthy subjects: a randomised crossover blinded trial", "acronym": null, "studyHypothesis": "The aim of this study was to evaluate the effect of beta-glucan on the rate of gastric emptying, post-prandial glucose response and satiety in healthy subjects.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "The beta-glucan effect on the rate of gastric emptying was statistically not significant compared with cornflakes. Consumption of beta-glucan lowered the post-prandial glucose response significant (p < 0.05).", "secondaryOutcome": "The effect of beta-glucan on satiety was not statistically significant.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN90535566", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR971"}, "trialDesign": {"studyDesign": "Randomised, double-blind, crossover trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Quality of life"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2003-04-01T00:00:00.000Z", "overallEndDate": "2004-01-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Netherlands", "Sweden"]}, "trialCentres": {"trialCentre": {"@id": "fee3facc-a8bb-4989-ac31-8f07a6f6dcd7", "name": "Malmo University Hospital", "address": null, "city": "Malmo", "state": null, "country": "Sweden", "zip": "205 02"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Healthy subjects without symptoms or a prior history of gastrointestinal disease, abdominal surgery or diabetes mellitus were included in the study.", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "12", "totalFinalEnrolment": null, "totalTarget": "12", "exclusion": "1. Diabetes mellitus\n2. Prior abdominal surgery\n3. Symptoms of gastrointestinal disease\n4. Obesity", "patientInfoSheet": null, "recruitmentStart": "2003-04-01T00:00:00.000Z", "recruitmentEnd": "2004-01-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Gastric emptying, post-prandial blood glucose", "diseaseClass1": "Nutritional, Metabolic, Endocrine", "diseaseClass2": "Gastric emptying in healthy subjects"}}, "interventions": {"intervention": {"description": "Twelve healthy subjects were assessed using a randomised crossover blinded trial. The subjects were examined after an eight-hour fast and assessment of normal fasting blood glucose level. Gastric emptying rate was calculated as the percentage change in the antral cross-sectional area 15 and 90 minutes after ingestion of vanilla yoghurt with flakes containing 4 g beta-glucan (GER1) or vanilla yoghurt with Kellogg's cornflakes (GER2). Significant differences were evaluated with Wilcoxon t-test.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Beta-glucan"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder16658-0", "contactId": "Contact54616_16658", "sponsorId": "Sponsor53171"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54616_16658", "title": "Dr", "forename": "Joanna", "surname": "Hlebowicz", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Malmo University Hospital\nDepartment of Medicine\nIngang 35", "city": "Malmo", "country": "Sweden", "zip": "205 02", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+46 (0)40 331 000"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "Joanna.Hlebowicz@skane.se"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor53171", "organisation": "Malm\u00f6 University Hospital (Sweden)", "website": "http://www.hand.mas.lu.se/malmo_unv_hosp.htm", "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "Department of Medicine\nIngang 35", "city": "Malm\u00f6", "country": "Sweden", "zip": "205 02", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.32995.34", "rorId": "https://ror.org/05wp7an13"}, "funder": {"@id": "Funder16658-0", "name": "Sk\u00e5nemejerier (Sweden)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-11-13T00:00:00.000Z", "@version": "17", "isrctn": {"@dateAssigned": "2006-12-28T00:00:00.000Z", "#text": "17633610"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "TEAM II: a randomised, multicentre, prospective, phase III trial investigating neoadjuvant hormonal therapy with exemestane for three versus six months (TEAM IIa) and/or the efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in post-menopausal women with hormone receptor positive early breast cancer (TEAM IIb)", "scientificTitle": null, "acronym": "TEAM II", "studyHypothesis": "TEAM IIa: Six months of neoadjuvant therapy with exemestane is superior to three months with respect to the rate of downsizing in post-menopausal women with oestrogen receptor (ER) positive (more than 50% of tumour cells positive) primary breast cancer.\n\nTEAM IIb: Adjuvant systemic therapy combined with oral ibandronate results in an improved three-years disease free survival compared to adjuvant systemic therapy without ibandronate in post-menopausal women with hormone receptor positive primary breast cancer.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "TEAM IIa:\nObjective response rate (immediately prior to surgery) of the primary breast tumour, assessed by palpation, which is preferably performed by the same person.\n\nTEAM IIb:\nThree years disease free survival.", "secondaryOutcome": "TEAM IIa:\n1. Objective response rate of the breast tumour by mammography (Response Evaluation Criteria in Solid Tumors [RECIST])\n2. Objective response rate of the breast tumour assessed by ultrasound (RECIST)\n3. Objective response rate of the breast tumour assessed by magnetic resonance imaging (MRI) (RECIST)\n4. Objective response rate of the regional lymph nodes assessed by ultrasound (RECIST)\n5. Pathological complete response rate of primary breast cancer\n6. Pathological complete response rate of eventually positive lymph nodes\n7. Number of patients who required a mastectomy before neoadjuvant therapy and for whom breast conserving surgery became feasible after neoadjuvant therapy (independent of actual surgical treatment received)\n8. Number of patients who required a mastectomy before neoadjuvant therapy and who received breast conserving surgery after neoadjuvant therapy\n9. Determination of predictive factors able to predict clinical and pathological response\n10. Collection of tumour samples for translational research to improve diagnostics and treatment of breast cancer\n\nTEAM IIb:\n1. Time to and rate of bone metastases as first occurrence, in patients treated with these regimens\n2. Time to and rate of bone metastases, per se, in patients treated with these regimens\n3. Time to and rate of visceral and other distant metastases in patients treated with these regimens\n4. Time to and rate of local- and locoregional recurrences in patients treated with these regimens\n5. Time to and rate of contralateral breast cancer in patients treated with these regimens\n6. Five years disease free survival\n7. Overall survival (all cause mortality and breast cancer specific mortality) in patients treated with these regimens\n8. Safety and toxicity of ibandronate in patients treated with this bisphosphonate\n9. Specific prognostic indicators for the development of bone metastases and factors that are able to predict specific benefit from ibandronate treatment in these patients using tissue micro-array and other modern techniques", "trialWebsite": "http://www.ikcnet.nl", "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from the Protocol Reviewing committee of the Netherlands Cancer Institute/Antoni van Leeuwenhoek Ziekenhuis (Protocol Toetsingscommissie van het Nederlands Kanker Insitituut/Antoni van Leeuwenhoek Ziekenhuis) on the 28th September 2006 (4th amendment) (ref: PTC06.1431/M06TM2)."}, "externalRefs": {"doi": "10.1186/ISRCTN17633610", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "BOOG 2006-04; NTR785"}, "trialDesign": {"studyDesign": "Multicentre, randomised, active controlled, parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-10-01T00:00:00.000Z", "overallEndDate": "2010-10-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "af61e71a-afc6-4693-8905-b60ed6f550ef", "name": "Leiden University Medical Centre (LUMC)", "address": null, "city": "Leiden", "state": null, "country": "Netherlands", "zip": "2300 RC"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "TEAM IIa:\n1. Female patients with histologically, by core needle biopsy-proven, invasive adenocarcinoma of the breast\n2. Any tumour with a size more than or equal to 2 cm (except cT4d = inflammatory breast cancer)\n3. Indication to receive adjuvant hormonal therapy according to most recent Nationaal Borstkanker Overleg Nederland (NABON) guideline\n4. ER expression more than 50% (progesterone receptor [PgR] either positive or negative)\n5. Post-menopausal women: post-menopausal defined as:\n5.1. Age more than or equal to 50 and amenorrhoea for more than one year\n5.2. Bilateral surgical oophorectomy and no hormone replacement therapy (HRT) (any age is acceptable)\n5.3. Age less than 50 with natural amenorrhoea more than one year at breast cancer diagnosis (and uterus in situ)\n5.4. Post-menopausal due to chemotherapy will be excluded\n5.5. In case of doubt about menopausal status, assessment of follicle stimulating hormone (FSH), luteinising hormone (LH) and oestradiol has to be performed to define the menopausal status\n6. World Health Organization (WHO) performance status zero or one\n7. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule\n8. Accessible for follow-up for the duration of the trial\n9. Before randomisation, patients must be capable of understanding the trial and give written informed consent according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (ICH/GCP) and local Institutional Review Board (IRB) guidelines\n\nTEAM IIb:\n1. Histological confirmed invasive adenocarcinoma of the breast\n2. Stage I to III breast cancer\n3. Completed adequate surgical treatment\n4. (Neo)adjuvant chemotherapy, radiotherapy and/or trastuzumab are allowed\n5. Indication to receive adjuvant hormonal therapy according to most recent NABON guideline\n6. ER and/or PgR receptor positive (ER expression more than or equal to 10% and/or PgR more than or equal to 10%)\n7. Known human epidermal growth factor receptor 2 (HER2) status\n8. Adequate renal- and hepatic function as assessed by laboratory testing within four weeks prior to enrolment:\n8.1. Renal function: creatinine less than or equal to 120 \u00b5mol/L. If limit values, the calculated creatinine clearance should be more than or equal to 30 mL/min with the Cockcroft and Gault-formula\n8.2. Hepatic function: total bilirubin less than or equal to 1.5 x upper normal limit (UNL); aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine transaminase (ALT) (serum glutamic pyruvic transaminase [SGPT]) less than or equal to 2.5 x UNL; alkaline phosphatase less than or equal to 2.5 x UNL\n9. Post-menopausal women: post-menopausal defined as:\n9.1. Age more than or equal to 50 and amenorrhoea for more than one year\n9.2. Bilateral surgical oophorectomy and no HRT (any age is acceptable)\n9.3. Age less than 50 with natural amenorrhoea more than one year at breast cancer diagnosis (and uterus in situ)\n9.4. Post-menopausal due to chemotherapy will be excluded\n9.5. In case of doubt about the menopausal status, assessment of FSH, LH and oestradiol has to be performed to define the menopausal status\n10. WHO performance status zero or one\n11. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule\n12. Accessible for follow-up for the duration of the trial\n13. Before randomisation, patients must be capable of understanding the trial and give written informed consent according to ICH/GCP, and local IRB guidelines", "ageRange": "Adult", "gender": "Female", "targetEnrolment": "2478", "totalFinalEnrolment": null, "totalTarget": "2478", "exclusion": "TEAM IIa:\n1. M1 disease by clinical examination according to the NABON guideline\n2. Multicentric breast cancer (including carcinoma in situ [CIS])\n3. Bilateral breast cancer (including CIS)\n4. cT4d tumour (inflammatory breast cancer)\n5. Hormone replacement therapy during the last 12 months\n6. One of the following diseases:\n6.1. Uncontrolled cardiac disease\n6.2. Psychiatric disorders preventing proper informed consent\n6.3. Concomitant malignancies within the last five years, except for adequately treated carcinoma in situ of the uterine cervix or basal squamous cell carcinoma of the skin\n6.4. Prior invasive breast cancer or CIS within the last 15 years\n6.5. Other serious illnesses that may interfere with subject compliance, adequate informed consent or determination of causality of adverse events\n7. Concurrent participation in another clinical study that may interfere with the results of the trial involving investigational agents within thirty days of treatment from this study, unless this is agreed by the Study Coordinators\n8. More than three weeks after date of histological biopsy of primary breast cancer\n\nTEAM IIb:\n1. M1 disease by clinical examination according to the NABON guideline\n2. Bilateral invasive breast cancer (including CIS)\n3. Patients having shown progressive disease in TEAM IIa (preoperative hormonal treatment with exemestane)\n4. One of the following diseases:\n4.1. Uncontrolled cardiac disease\n4.2. Psychiatric disorders preventing proper informed consent\n4.3. Patients with untreated oesophagitis, gastric ulcers or irritable bowel disease (IBD)\n4.4. Concomitant malignancies within the last five years, except for adequately treated carcinoma in situ of the uterine cervix or basal squamous cell carcinoma of the skin\n4.5. Prior invasive breast cancer and/or CIS within the last 15 years\n4.6. Other serious illnesses that may interfere with subject compliance, adequate informed consent or determination of causality of adverse events\n5. History of disease with influence on bone metabolism, including:\n5.1. Pagets disease of the bone\n5.2. Primary hyperparathyroidism (patients cured by surgery may be included if interval more than or equal to one year)\n6. Hormone replacement therapy during the last 12 months\n7. Current active dental problems including dental abscess or infection of the jawbone (maxilla or mandible), or a current or prior diagnosis of osteonecrosis of the jaw requiring maxillo-facial surgery\n8. Recent (within four weeks of study entry) or planned dental or jaw surgery (e.g. extraction, implants). Recent dental fillings, teeth scaling and polishing or minor gingival surgery do not exclude the patient\n9. Concurrent participation in another clinical study that may interfere with the results of the trial involving investigational agents within thirty days of treatment from this study, unless this is agreed by the Study Coordinators\n10. More than five weeks after final surgery or after end of adjuvant chemotherapy", "patientInfoSheet": null, "recruitmentStart": "2006-10-01T00:00:00.000Z", "recruitmentEnd": "2010-10-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Breast cancer", "diseaseClass1": "Cancer", "diseaseClass2": "Malignant neoplasm of the breast"}}, "interventions": {"intervention": {"description": "TEAM IIa: \nPatients will be randomised (1:1) between three versus six months of neoadjuvant therapy with exemestane (25 mg once daily). After surgery, patients may be randomised in the adjuvant part of the study (TEAM IIb) if the adjuvant inclusion criteria are met.\n\nTEAM IIb: \nPatients will be randomised (1:1) to oral ibandronate (50 mg once daily) for three years added to standard adjuvant systemic treatment or to standard adjuvant systemic therapy only. Hormonal treatment will be according to the most recent NABON guideline. Exemestane will be used as aromatase inhibitor.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Phase III", "drugNames": "Exemestane, ibandronate"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder15981-0", "contactId": "Contact53927_15981", "sponsorId": "Sponsor52476"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact53927_15981", "title": "Prof", "forename": "C J H", "surname": "van de Velde", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Leiden University Medical Centre (LUMC)\nDepartment of Surgical Oncology\nP.O. Box 9600", "city": "Leiden", "country": "Netherlands", "zip": "2300 RC", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)71 526 2309"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "c.j.h.van_de_velde@lumc.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor52476", "organisation": "TEAM II Study Group (The Netherlands)", "website": null, "sponsorType": "Other", "contactDetails": {"address": "-", "city": "Alkmaar", "country": "Netherlands", "zip": "-", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "funder": {"@id": "Funder15981-0", "name": "Leiden University Medical Centre (LUMC) (The Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-11-13T00:00:00.000Z", "@version": "18", "isrctn": {"@dateAssigned": "2006-01-27T00:00:00.000Z", "#text": "34634478"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Second Dutch Lupus Nephritis trial", "scientificTitle": "Comparison of short course cyclophosphamide followed by mycophenolate mofetil versus long course cyclophosphamide in the treatment of proliferative lupus nephritis", "acronym": null, "studyHypothesis": "Short course cyclophosphamide followed by mycophenolate mofetil will reduce renal relapses to 33% (versus 10% in patients treated with long-course cyclophosphamide)", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Number of renal relapses", "secondaryOutcome": "1. Longitudinal follow-up of creatinine, proteinuria, sediment, complement levels, anti-double stranded deoxyribonucleic acid (anti-dsDNA), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Systemic Lupus International Collaborating Clinics (SLICC), Dutch lupus nephritis questionnaire, 36-item short form health survey (SF-36), renal histology, IF-skin\n2. Extra-renal exacerbations of SLE \n3. Pregnancy\n4. Death", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from the local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN34634478", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR452"}, "trialDesign": {"studyDesign": "Multicentre, randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2003-01-01T00:00:00.000Z", "overallEndDate": "2008-01-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "46655080-4ab0-46d4-8024-ebef2548e11a", "name": "University Medical Centre Groningen", "address": null, "city": "Groningen", "state": null, "country": "Netherlands", "zip": "9700 RB"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Aged 18 - 70 years\n2. Systemic lupus erythematosus (SLE) (presence of at least 4 American College of Rheumatology [ACR]-criteria for SLE)\n3. Proliferative lupus nephritis:\n3.1. Biopsy proven lupus nephritis World Health Organization (WHO) class III or IV (according to Churg 1995) \n3.2. 'Active sediment': greater than 5 erythrocytes per high powered field (HPF) and/or cel cylinders \n3.3. Proteinuria greater than 0.5 g/day   \n4. Adequate contraception \n5. Informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "124", "totalFinalEnrolment": null, "totalTarget": "124", "exclusion": "1. Active infection\n2. Pregnancy\n3. Known allergy for one of the study drugs\n4. Malignancy less than 5 years prior to inclusion", "patientInfoSheet": null, "recruitmentStart": "2003-01-01T00:00:00.000Z", "recruitmentEnd": "2008-01-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Proliferative lupus nephritis", "diseaseClass1": "Musculoskeletal Diseases", "diseaseClass2": "Systemic lupus erythematosus"}}, "interventions": {"intervention": {"description": "Patients will be randomised between long-cyclophosphamide (six monthly courses, 750 mg/m^2) followed by either six 3-monthly courses cyclophosphamide or mycophelolate mofetil, both regimes in combination with prednisone. After 2 years all patients will continue for another 2 years with maintenance therapy, consisting of azathioprine 2 mg/kg.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Cyclophosphamide, mycophenolate mofetil"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14664-0", "contactId": "Contact52423_14664", "sponsorId": "Sponsor50938"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52423_14664", "title": "Dr", "forename": "Marc", "surname": "Bijl", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "University Medical Centre Groningen\nDepartment of Clinical Immunology\nP.O. Box 30.001", "city": "Groningen", "country": "Netherlands", "zip": "9700 RB", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)50 3612945"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "m.bijl@int.umcg.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50938", "organisation": "Sponsor not yet defined (The Netherlands)", "website": null, "sponsorType": "Not defined", "contactDetails": {"address": "-", "city": "-", "country": "Netherlands", "zip": "-", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "funder": {"@id": "Funder14664-0", "name": "Dutch Kidney Foundation (Nierstichting Nederland) (The Netherlands)", "fundRef": "http://dx.doi.org/10.13039/501100002997"}}, {"trial": {"@lastUpdated": "2008-11-13T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2005-12-20T00:00:00.000Z", "#text": "45377814"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Interactive Computer Tailored smoking cessation and prevention for Adolescents", "scientificTitle": null, "acronym": "ICTA", "studyHypothesis": "Intervention lead to 5% less smoking uptake and 10% more quit attempts.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Smoking status (and secondary outcomes) will be assessed with questionnaires which adolescents fill out on the Internet. At baseline and 6 and 12 months after baseline questionnaires will be filled out.", "secondaryOutcome": "1. Intention to smoke\n2. Intention to quit smoking\n3. Cognitive factors related to smoking (cessation)", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN45377814", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "ZonMw: 2100.0071; NTR345"}, "trialDesign": {"studyDesign": "Randomised, active controlled, parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2002-10-01T00:00:00.000Z", "overallEndDate": "2007-10-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "bccf9123-718f-4754-9554-b0007b3b757c", "name": "Maastricht University", "address": null, "city": "Maastricht", "state": null, "country": "Netherlands", "zip": "6200 MD"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Adolescents between 15 and 18 years old.", "ageRange": "Child", "lowerAgeLimit": {"@unit": "Years", "@value": "15.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "5000", "totalFinalEnrolment": null, "totalTarget": "5000", "exclusion": "Adolescents who do not attend school", "patientInfoSheet": null, "recruitmentStart": "2002-10-01T00:00:00.000Z", "recruitmentEnd": "2007-10-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Smoking cessation", "diseaseClass1": "Mental and Behavioural Disorders", "diseaseClass2": "Mental and behavioural disorders due to use of tobacco"}}, "interventions": {"intervention": {"description": "Two intervention groups receive three times a personalised advice on (quitting) smoking through Internet or letter after filling out a questionnaire on the Internet. The control group receives no personalised advice.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14540-0", "contactId": "Contact52128_14540", "sponsorId": "Sponsor50752"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52128_14540", "title": "Dr", "forename": "Froukje", "surname": "Dijk", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Maastricht University\nDepartment of Health Promotion and Health Education\nP.O. Box 616", "city": "Maastricht", "country": "Netherlands", "zip": "6200 MD", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)43 388 2406"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "f.dijk@gvo.unimaas.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50752", "organisation": "University Maastricht (UM) (The Netherlands)", "website": null, "sponsorType": "University/education", "contactDetails": {"address": "P.O. Box 616", "city": "Maastricht", "country": "Netherlands", "zip": "6200 MD", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.5012.6", "rorId": "https://ror.org/02jz4aj89"}, "funder": {"@id": "Funder14540-0", "name": "The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-11-13T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2005-12-20T00:00:00.000Z", "#text": "42389025"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Effect-evaluation of the intervention \"Being active without Worries\"", "scientificTitle": "Effect-evaluation of the intervention \"Being active without Worries\": an intervention aimed at reducing depressive and stress symptomatology in adult low socioeconomic status (LSES) women from disfavourised communities", "acronym": null, "studyHypothesis": "1. Can a larger percentage of low socioeconomic status (LSES) women with depressive and/or stress related symptomatology be reached with an intervention when this contains an exercise component?\n2. How effective is exercise only (B) compared to a control group (C) and does exercise plus psycho-education (BP) offer a surplus value above B?\n3. How do LSES women appreciate this new intervention?", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Depressive and stress related symptomatology, as measured by the CES-D, perceived stress scale, daily hassles scale. These measures will be administered two weeks before subjects start the course, 1 week after ending the course and next 6, 12 and 18 months after ending the course.", "secondaryOutcome": "1. Social support\n2. Mastery\n3. Self-esteem\n4. Self-efficacy\n5. Assertiveness \n6. Neighborhood perception\n\nThese will be measured two weeks before subjects start the course, 1 week after ending the course and next 6, 12 and 18 months after ending the course by means of questionnaires such as the Social Support List (SSL), personal mastery scale, the NPV, ALCOS and the SIG. Percentage of participating women will be determined by means of enrolment numbers for the course, satisfaction with the course will be determined by means of a questionnaire.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from the local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN42389025", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "ZonMw 4016.0004; NTR197"}, "trialDesign": {"studyDesign": "Randomised, single-blind, active controlled, parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2005-08-30T00:00:00.000Z", "overallEndDate": "2009-08-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "140c22bc-d5fb-4aff-8c58-184558614616", "name": "Maastricht University", "address": null, "city": "Maastricht", "state": null, "country": "Netherlands", "zip": "6200 MD"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. The research population consists of adult women (20 - 55 years) with a LSES background\n2. Furthermore, the women must have mild to moderate (sub-clinical) depressive symptomatology as measured with the Centre for Epidemiologic Studies Depression Scale (CES-D), or suffer from stress related complaints", "ageRange": "Adult", "gender": "Female", "targetEnrolment": "240", "totalFinalEnrolment": null, "totalTarget": "240", "exclusion": "Because of the design of the intervention, participants are not allowed to have severe hearing problems or severe physical handicaps", "patientInfoSheet": null, "recruitmentStart": "2005-08-30T00:00:00.000Z", "recruitmentEnd": "2009-08-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Depressive and stress related symptomatology", "diseaseClass1": "Mental and Behavioural Disorders", "diseaseClass2": "Depressive episode"}}, "interventions": {"intervention": {"description": "1. B-condition: the eight week intervention is offered with only the exercise component\n2. BP-condition: the eight week intervention is offered with the exercise and psycho-education components\n3. AC-condition: a control condition with postponed intervention for 3 months", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14414-0", "contactId": "Contact52172_14414", "sponsorId": "Sponsor50752"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52172_14414", "title": "Dr", "forename": "Judith", "surname": "van der Waerden", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Maastricht University\nDepartment of Health Education and Promotion\nP.O. Box 616", "city": "Maastricht", "country": "Netherlands", "zip": "6200 MD", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor50752", "organisation": "University Maastricht (UM) (The Netherlands)", "website": null, "sponsorType": "University/education", "contactDetails": {"address": "P.O. Box 616", "city": "Maastricht", "country": "Netherlands", "zip": "6200 MD", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.5012.6", "rorId": "https://ror.org/02jz4aj89"}, "funder": {"@id": "Funder14414-0", "name": "The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-11-13T00:00:00.000Z", "@version": "24", "isrctn": {"@dateAssigned": "2005-12-20T00:00:00.000Z", "#text": "02859773"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Lycopene and vitamin E in men with minimal prostate cancer and rising prostate specific antigen after radical prostatectomy: a double blind randomised placebo controlled cross-over study", "scientificTitle": null, "acronym": "BASF dietary study", "studyHypothesis": "The goal of this protocol is to show an effect of a dietary supplement on prostate specific antigen (PSA) progression. This will be measured by the impact of the dietary supplement on the slope of a documented PSA rise, which is translatable into an effect on PSA doubling time. This approach is considered by the study group as the closest approximation of a tertiary prevention study, which is at this moment clinically feasible.\nExtra safeguards will be filled in by run-in and washout periods, as well as by conducting animal experimental studies on human prostate cancer lines in nude mice.\n\nThe present protocol should produce evidence that may lead to the justification of more extensive studies that would more definitely establish the value of dietary intervention with supplements.\n\nHypothesis:\nA combination of Lycopene and Vitamin E decreases PSA progression.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Slope of the regression line through all two-weekly PSA measurements.", "secondaryOutcome": "Plasma levels of testosterone, oestradiol, dehydroepiandrosterone (DHEA), dihydrotestosterone (DHT), and sex hormone-binding globulin (SHBG), and insulin-like growth factor 1 (IGF-1) during the intervention as compared to placebo.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from the local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN02859773", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "A300205; NTR126"}, "trialDesign": {"studyDesign": "Randomised, placebo controlled, crossover group, double blinded multicentre trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2003-01-27T00:00:00.000Z", "overallEndDate": "2006-06-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "c42147b3-9ac1-42e9-b782-1443cc10a9d1", "name": "Department of Urology", "address": null, "city": "Rotterdam", "state": null, "country": "Netherlands", "zip": "3000 CA"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Status after radical prostatectomy with potential curative intent\n2. Rising PSA\n3. Life expectancy more than or equal to 12 months\n4. Age more than or equal to 18 years", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Male", "targetEnrolment": "80", "totalFinalEnrolment": null, "totalTarget": "80", "exclusion": "1. Current hormone therapy or hormone therapy during previous 12 months\n2. Orchidectomy\n3. Chemotherapy, radiotherapy or transurethral resection of the prostate (TURP) prior to study resulting in PSA decrease that is currently ongoing", "patientInfoSheet": null, "recruitmentStart": "2003-01-27T00:00:00.000Z", "recruitmentEnd": "2006-06-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Prostate cancer", "diseaseClass1": "Cancer", "diseaseClass2": "Malignant neoplasm of prostate"}}, "interventions": {"intervention": {"description": "Lycopene 15 mg and Vitamin E 400 IU each day during 12 weeks versus placebo. After a washout period, a cross-over will take place.", "interventionType": "Supplement", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Lycopene, Vitamin E"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16263208 Results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "82d8deac-e783-4366-b21f-16f301cb6247", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2005-12-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/16263208"}, "description": "Results", "productionNotes": null}}, "parties": {"funderId": "Funder14347-0", "contactId": "Contact52256_14347", "sponsorId": "Sponsor50575"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52256_14347", "title": "Prof", "forename": "F.H.", "surname": "Schr\u00f6der", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Department of Urology \nErasmus Medical Centre\nP.O. Box 2040", "city": "Rotterdam", "country": "Netherlands", "zip": "3000 CA", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)10 463 4328"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "e.vandenberg@erasmusmc.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50575", "organisation": "BASF Aktiengesellschaft (Germany)", "website": "http://corporate.basf.com/de/?id=V00-MtkCyA4GZbcp.sn", "sponsorType": "Industry", "contactDetails": {"address": "Carl-Bosch-Str. 38", "city": "Ludwigshafen", "country": "Germany", "zip": "DE-67063", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.3319.8", "rorId": "https://ror.org/01q8f6705"}, "funder": {"@id": "Funder14347-0", "name": "Not provided at time of registration", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-11-13T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2005-12-20T00:00:00.000Z", "#text": "00662276"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "The effects of parent training on behaviour problems, attention deficit hyperactivity disorder (ADHD) symptoms and parenting stress in children with ADHD in routine child psychiatric out-patient care", "scientificTitle": null, "acronym": null, "studyHypothesis": "1. Parent training will lead to a significant reduction of behaviour problems in comparison with routine medical care\n2. Parent training will be as effective as routine medical care with respect to the reduction of ADHD symptoms\n3. Parent training will lead to a significant reduction of parenting stress in comparison with routine medical care", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Target behaviour problems. Measures: a Dutch adaptation of the PDR and CBCL Externalising.\n2. Adhd-symptoms. Measures: all subscales of the CPRS-R:S.\n3. Parenting stress. Measures: Parent Domain and Child Domain of the NOSI (Dutch version of the PSI).\n\nAssessments on all measures pre-treatment and post-treatment. A follow-up assessment on all measures after 5 months was done for the parents in the PT group.", "secondaryOutcome": "1. Internalising problems. Measure: CBCL Internalising. Assessment pre-treatment and post-treatment. A follow-up assessment after 5 months was done for the parents in the PT group.\n2. Medication status. Monitoring during the study by the child psychiatrist.\n3. Consumption of routine medical care. Monitoring during the study by the child-psychiatrist.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from the local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN00662276", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR297"}, "trialDesign": {"studyDesign": "Randomised, active controlled, parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2002-06-01T00:00:00.000Z", "overallEndDate": "2005-05-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "5cb31def-722f-47aa-bf0c-a67d27da072b", "name": "University Medical Centre Groningen", "address": null, "city": "Groningen", "state": null, "country": "Netherlands", "zip": "9713 GZ"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Age between 4 and 12 years\n2. Average intelligence quotient (IQ) greater than 80\n3. Meeting Diagnostic Interview Schedule for Children (DISC) criteria for ADHD\n4. Children under the age of 6 need an additional AVL-score greater than 32\n5. Parents can identify at least three target behaviour problems on the PDR\n6. Child is living with at least one of his/her biological parents\n7. Child medication status is stable\n8. Both parents are able to participate in parent training", "ageRange": "Child", "lowerAgeLimit": {"@unit": "Years", "@value": "4.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "12.0"}, "gender": "Both", "targetEnrolment": "96", "totalFinalEnrolment": null, "totalTarget": "96", "exclusion": "1. Diagnosis of autism or psychosis\n2. Crisis in family\n3. Intensive psychosocial treatment in past year, including in-patient treatment, intensive parent training, home-based treatments\n4. Child having additional problems requiring other treatment", "patientInfoSheet": null, "recruitmentStart": "2002-06-01T00:00:00.000Z", "recruitmentEnd": "2005-05-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Attention deficit hyperactivity disorder (ADHD), psychological problems", "diseaseClass1": "Mental and Behavioural Disorders", "diseaseClass2": "Hyperkinetic disorders"}}, "interventions": {"intervention": {"description": "1. Parent training in group format, 12 sessions in a period of 4 months, delivered by trained and supervised psychologists\n2. Routine medical care for 4 months, delivered by 4 experienced child psychiatrists, including medication treatment and check-ups, crisis-interventions, parent counselling and support, further psycho-education", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14501-0", "contactId": "Contact52106_14501", "sponsorId": "Sponsor50713"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52106_14501", "title": "Dr", "forename": "Barbara J.", "surname": "van den Hoofdakker", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "University Medical Centre Groningen\nUniversity Center for Child and Adolescent Psychiatry\nDepartment of Psychiatry\nHanzeplein 1", "city": "Groningen", "country": "Netherlands", "zip": "9713 GZ", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)50 3681100"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "b.van.den.hoofdakker@accare.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50713", "organisation": "National Expertise Centre for Child and Adolescent Psychiatry (Accare) (The Netherlands)", "website": "http://www.accare.nl/", "sponsorType": "University/education", "contactDetails": {"address": "P.O. Box 660", "city": "Groningen", "country": "Netherlands", "zip": "9700 AR", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)50 3610973"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "info@accare.nl"}}, "privacy": "Public", "gridId": "grid.459337.f", "rorId": "https://ror.org/02h4pw461"}, "funder": {"@id": "Funder14501-0", "name": "University Medical Centre Groningen (UMCG) (The Netherlands) - Stimuleringsgelden", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-11-13T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2005-12-19T00:00:00.000Z", "#text": "66748327"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Prevention of asthma in children at high risk of developing asthma", "scientificTitle": "Prevention of asthma in children at high risk of developing asthma by advising parents on reducing environmental exposures", "acronym": "PREVASC-OMEGA", "studyHypothesis": "Children in the intervention group will show to have less asthma symptoms and a better lung function than children in the control group as measured at age 6 years by questionnaire (symptoms), general practitioners registration (symptoms), and lung function measurements (microRint, FEHO, forced expiratory volume in one second (FEV1), PC20, reversibility).", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Current asthma 6 years as measured in lung function laboratory combined with asthma complaints as registered by General Practitioner and/or parents (questionnaires).", "secondaryOutcome": "1. Asthma diagnosis  by General Practitioner\n2. Asthma symptoms 0 - 6 years (questionnaires)\n3. Asthma symptoms 0 - 6 years (General Practitioner)\n4. Hospital admission for asthma symptoms\n5. Allergy (as registered by parents, general practitioner, IgE measurements project)", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from the local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN66748327", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR371"}, "trialDesign": {"studyDesign": "Multicentre, randomised, single-blind, active controlled, parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "GP practice"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "1997-01-01T00:00:00.000Z", "overallEndDate": "2007-07-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "1a65e89e-7bed-4d44-ac29-b5ee9b573c15", "name": "University Maastricht (UM)", "address": null, "city": "Maastricht", "state": null, "country": "Netherlands", "zip": "6200 MD"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "General practitioners, midwives and gynaecologists were instructed to check the inclusion criteria:\n1. Pregnant women less than 7 months gestational age\n2. Unborn child at high risk of developing asthma on grounds of familial predisposition first degree\n3. Living in study region", "ageRange": "Adult", "gender": "Female", "targetEnrolment": "443", "totalFinalEnrolment": null, "totalTarget": "443", "exclusion": "1. Major language problem\n2. Intrauterine or neonatal death\n3. Moving outside the Netherlands\n4. Severe illness/malformation child", "patientInfoSheet": null, "recruitmentStart": "1997-01-01T00:00:00.000Z", "recruitmentEnd": "2007-07-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Asthma", "diseaseClass1": "Respiratory", "diseaseClass2": "Asthma"}}, "interventions": {"intervention": {"description": "Advisory intervention on reducing exposure to:\n1. Allergen exposure (house dust mite, cat and dog allergens)\n2. Food allergens by exclusively breastfeeding for a period of 6 months or if not possible feeding the child with hypo-allergenic formula, introducing solids until 6 months\n3. Environmental tobacco smoke (parents stop smoking)\nControl group: usual care", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": ["Funder14294-0", "Funder14294-1"], "contactId": "Contact52043_14294", "sponsorId": "Sponsor50505"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52043_14294", "title": "Prof", "forename": "C P", "surname": "van Schayck", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "University Maastricht (UM)\nCAPHRI Research Institute\nDepartment of General Practice\nP.O. Box 616", "city": "Maastricht", "country": "Netherlands", "zip": "6200 MD", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor50505", "organisation": "University Maastricht (UM) (The Netherlands)", "website": null, "sponsorType": "University/education", "contactDetails": {"address": "P.O. Box 616", "city": "Maastricht", "country": "Netherlands", "zip": "6200 MD", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.5012.6", "rorId": "https://ror.org/02jz4aj89"}, "funder": [{"@id": "Funder14294-0", "name": "The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)", "fundRef": null}, {"@id": "Funder14294-1", "name": "Netherlands Asthma Foundation (The Netherlands)", "fundRef": null}]}, {"trial": {"@lastUpdated": "2008-11-13T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2005-12-19T00:00:00.000Z", "#text": "11571826"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "An open label randomised controlled study in elderly subjects with previously untreated acute myelogenous leukaemia, comparing treatment groups randomised to receive daunorubicin and cytarabine or daunorubicin, cytarabine and PSC-833", "scientificTitle": null, "acronym": "HOVON 31 AML/Novartis PSC C 302-E-00", "studyHypothesis": "Evaluation of the effect of PSC-833 during induction treatment with daunorubicin and cytarabine.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Event-free survival", "secondaryOutcome": "1. Complete remission \n2. Disease-free survival\n3. Overall survival\n4. Association between complete remission and expression of P-gp by AML-blasts", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from the local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN11571826", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "HO31; NTR360"}, "trialDesign": {"studyDesign": "Multicentre, open label, randomised, active controlled, parallel group study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "1997-05-12T00:00:00.000Z", "overallEndDate": "1999-02-17T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "32a58bd5-009e-4d10-a52f-2fdf229b2dc9", "name": "Erasmus Medical Center", "address": null, "city": "Rotterdam", "state": null, "country": "Netherlands", "zip": "3008 AE"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Aged greater than or equal to 60 years\n2. Subjects who have a cytopathologically confirmed diagnosis of previously untreated AML (M0-M2 and M4-M7, FAB classification)\n3. Subjects with secondary AML progressing from antecedent MDS are eligible if there has been no previous chemotherapy. Antecedent MDS is defined as any antecedent haematological disease of at least 4 months duration.\n4. World Health Organization (WHO) performance status less than or equal to 2\n5. Subjects have given written informed consent", "ageRange": "Senior", "gender": "Both", "targetEnrolment": "400", "totalFinalEnrolment": null, "totalTarget": "400", "exclusion": "1. Cytopathologically confirmed central nervous system (CNS) infiltration. NB: in the absence of clinical suspicion of CNS involvement, lumbar puncture is not required.\n2. Subjects have had previous Polycythemia Rubra Vera, primary myelofibrosis, are in blast cell crisis of chronic myeloid leukaemia or are M3 AML according to FAB classification\n3. Subject has neurosensory toxicity greater than or equal to Grade 2 (NCIC Expanded CTC)\n4. Subject has neurocerebellar toxicity greater than or equal to Grade 1 (NCIC Expanded CTC)\n5. Subject is known to be positive for human immunodeficiency virus (HIV) type 1 antibody (testing to determine HIV antibody status is not necessary to be eligible)\n6. Subject has impairment of hepatic or renal function as defined by the following baseline laboratory values:\n6.1. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) greater than or equal to 2.5 times IULN\n6.2. Alkaline phosphatase greater than or equal to 2.5 times IULN\n6.3. Serum total bilirubin greater than or equal to 1.5 times IULN\n6.4. Serum creatinine greater than or equal to 1.5 times IULN after adequate hydration\n7. Subject is currently receiving treatment with any of the agents listed in the protocol if treatment cannot be discontinued at the specified time relative to PSC-833 administration. All of the drugs listed are well substantiated to interact with cyclosporin A.\n8. Subject has had major surgery within 2 weeks of study entry\n9. Subject has received investigational therapy within 30 days of study entry\n10. Subject has known hypersensitivity to cyclosporin A\n11. Subject has received prior radiotherapy within 4 weeks of study entry\n12. Subject is less than 5 years free of another primary malignancy with the exception of basal cell carcinoma of the skin and stage 1 cervical carcinoma\n13. Subject has previously been treated with chemotherapy for AML\n14. Subject has concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension etc.)\n15. Subject has a psychological, intellectual or sensory dysfunction which is likely to impede their ability to understand and comply with study requirements\n16. Subject had a myocardial infarction within the last 6 months, has symptomatic ischaemic heart disease, congestive heart failure or other uncontrolled coronary disease", "patientInfoSheet": null, "recruitmentStart": "1997-05-12T00:00:00.000Z", "recruitmentEnd": "1999-02-17T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Acute myeloid leukaemia (AML)", "diseaseClass1": "Cancer", "diseaseClass2": "Myeloid leukaemia"}}, "interventions": {"intervention": {"description": "Patients with AML, meeting all eligibility criteria will be randomised on entry between:\nArm A: two induction cycles of daunorubicin (DNR) 45 mg/m^2/day, days 1 - 3 and cytarabine (Ara-C) 200 mg/m^2/day, days 1 - 7, or \nArm B: two induction cycles of DNR 35 mg/m^2/day, days 1 - 3; Ara-C 200 mg/m^2/day, days 1 - 7; and PSC-833 loading dose 2 mg/kg over 2 hours, followed by 10 mg/kg/day, days 1 - 3\n\nPatients in CR will then be given one consolidation cycle without PSC-833 consisting of Ara-C, mitoxantrone and etoposide.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Daunorubicin, cytarabine, PSC-833"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15994288 Results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "3a838270-c4c1-4ddd-b7de-cf09da5cc847", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2005-10-15T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/15994288"}, "description": "Results", "productionNotes": null}}, "parties": {"funderId": ["Funder14327-0", "Funder14327-1"], "contactId": "Contact52071_14327", "sponsorId": "Sponsor50538"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52071_14327", "title": "Prof", "forename": "B.", "surname": "L\u00f6wenberg", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Erasmus Medical Center\nDaniel den Hoed Cancer Center\nDepartment of Hematology\nP.O. Box 5201", "city": "Rotterdam", "country": "Netherlands", "zip": "3008 AE", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)10 4391598"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "b.lowenberg@erasmusmc.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50538", "organisation": "Novartis Pharma AG (Switzerland)", "website": null, "sponsorType": "Industry", "contactDetails": {"address": "-", "city": "Basel", "country": "Switzerland", "zip": "CH-4002", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.419481.1", "rorId": "https://ror.org/02f9zrr09"}, "funder": [{"@id": "Funder14327-0", "name": "Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands)", "fundRef": null}, {"@id": "Funder14327-1", "name": "Novartis Pharma B.V. (The Netherlands)", "fundRef": null}]}]}}